2Matthews DR, Hoskey JP, Rudenski AS. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man[J]. Diabetologia, 1985, 28 (7): 412-419. 被引量：1
3Mastorakos G, Koliopoulos C, Creatsas G. Androgen and lipid profilesion adolescents with polycystic ovary syndrome who were treated with two forms of combined oral contraceptives [J]. Fertil Steril, 2002, 77 (5): 919-927. 被引量：1
4Bhathena RK. Insulin resistance and the long-term consequences of poly-cystic ovary syndrome. J Obstet Gynaecol,2011,31:105-110. 被引量：1
5Panidis D, Georgopoulos NA, Piouka A, et al. The impact of oral contra- ceptives and metformin on anti-Mtlllerian hormone serum levels in women with polycystic ovary syndrome and biochemical hyperandrogenemia. Gy- necol Endocrino1,2011,27 : 1-6. 被引量：1
6Tfayli H, Ulnach JW, Lee S, et al. Drospirenone/ethinyl estradiol versus rosiglitazone treatment in overweight adolescents with polyeystic ovary syn- drome:comparison of metabolic, hormonal, and cardiovascular risk fac-tors. J Clin Endocrinol Metab,2011,96 : 1311-1319. 被引量：1
7Fruzzetti F, Perini D, Lazzarini V, et al. Comparison of effects of 3 mg dro- spirenone plus 20 g.g ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular risk factors in nonobese women with polycystic ovary syndrome. Fertil Steril, 2010,94 : 1793-1798. 被引量：1
